(Press-News.org) According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumours, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.
“The results are highly interesting in oncology, as we show that a lower dose of an immunotherapy drug, in addition to causing significantly fewer side effects, actually gives better results against tumours and longer survival,” says last author Hildur Helgadottir, a researcher at the Department of Oncology-Pathology at Karolinska Institutet, who led the study.
The traditional dose of nivolumab and ipilimumab is the one that is approved and established. Due to the extensive side effects, Sweden has increasingly begun to use a treatment regimen with a lower dose of ipilimumab, which is the most expensive part of this immunotherapy and causes the most side effects.
“In Sweden, we have greater freedom to choose doses for patients, while in many other countries, due to reimbursement policies, they are restricted by the doses approved by the drug authorities,” says Hildur Helgadottir.
The study included nearly 400 patients with advanced, inoperable malignant melanoma, the most serious form of skin cancer. The study shows that the regimen with the lower dose of ipilimumab is more effective, with a higher proportion of patients responding to treatment, 49 percent, compared to the traditional dose, 37 percent.
Progression-free survival, the time the patient lives without the disease worsening, was a median of nine months for the lower dose, compared to three months for the traditional dose. Overall survival was also longer, 42 months compared to 14 months.
Serious side effects were seen in 31 percent of patients in the low-dose group, compared to 51 percent in the traditional group.
"The new immunotherapies are very valuable and effective, but at the same time they can cause serious side effects that are sometimes life-threatening or chronic. Our results suggest that this lower dosage may enable more patients to continue the treatment for a longer time, which is likely to contribute to the improved results and longer survival," says Hildur Helgadottir.
There were some differences between the two treatment groups, but even after adjusting for several factors such as age and tumour stage, the better outcome for the lower dose of ipilimumab remained. The study is a retrospective observational study and therefore it is not possible to definitively establish a causal relationship.
The study was conducted in collaboration with the Sahlgrenska Comprehensive Cancer Center at Sahlgrenska University Hospital and was funded by the Cancer Foundation, Region Stockholm, and the Radiumhemmet Research Fund. See the study for any conflicts of interest.
Publication: Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma, Karl Björkström, Cissi Liu, Anna Fager, Lisa L. Liu, Lars Ny, Hildur Helgadottir, Journal of the National Cancer Institute, online 8 December 2025, doi: 10.1093/jnci/djaf327.
END
Lower doses of immunotherapy for skin cancer give better results
2025-12-08
ELSE PRESS RELEASES FROM THIS DATE:
Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility
2025-12-08
Road crossings need to slow down to allow people with mobility issues and older pedestrians enough time to use them, research has indicated.
The time interval of crossings in the UK is more than two seconds shorter than people with reduced mobility need, according to a new study by researchers at the Universities of Bath, Birmingham and Exeter.
Led by Dr Max Western from the University of Bath Centre for Motivation and Behaviour Change, the study found that just 1.5% of older adults with ...
ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment
2025-12-07
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 7, 2025, AT 6:00 P.M. EST) – Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.
Early findings from the LIFE-L study will be presented on behalf of the multidisciplinary team by Melissa Lopez, Ph.D., RDN, at the American Society of Hematology (ASH) annual meeting in Orlando. Lopez is a postdoctoral ...
A sound defense: Noisy pupae puff away potential predators
2025-12-07
Insect pupae hiss like snakes for defense. A Kobe University team now reveals the mechanisms, opening the door to further studies involving predator reactions to defensive sounds.
Just as you would shout or make noise to drive off a perceived threat, some insects have been known to produce defensive sounds. Some moths, for example, have been observed producing sounds to ward off predators at multiple developmental stages; pupal sound production has so far been attributed mainly to physical friction between body parts. “We became interested in this topic when ...
Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax combination (known as aza-ven) is the standard of care for older adults who are not fit enough for intensive chemotherapy. The trial is the first to test the superiority of this regimen to intensive induction chemotherapy, the current standard for fit patients.
“Our study met ...
Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone. The study is the first reported randomized controlled trial to test a bispecific antibody combination in follicular lymphoma and suggests the combination could offer an effective alternative to chemotherapy that can be safely administered on an outpatient basis.
Based on the study results, the U.S. Food and Drug Administration (FDA) approved epcoritamab with ...
New findings support a chemo-free approach for treating Ph+ ALL
2025-12-07
(ORLANDO, Dec. 7, 2025) A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL.
Researchers say the findings offer reassurance that chemotherapy can be omitted without detrimental effects and suggest that a chemo-free targeted agent and immunotherapy combination could become the new standard of care for this patient group.
“The chemo-free approach ...
Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL
2025-12-07
(ORLANDO, Dec. 7, 2025) Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study results, researchers suggest pirtobrutinib shows promise as initial BTK inhibitor therapy, including in the frontline setting, for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Non-covalent BTK inhibitors were initially developed to overcome resistance to covalent ...
University of Cincinnati experts present research at annual hematology event
2025-12-06
University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6 to 9 in Orlando.
Phase 1 data testing new CLL treatment encouraging
A class of drugs called BTK inhibitors have become a standard treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). However, the prevalence of new resistance mutations has created a need for new treatments in patients with relapsed CLL who progressed through approved standard of care options, said the Cancer Center’s Zulfa Omer, MD.
“This is an area of unmet need, with current options providing ...
ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial
2025-12-06
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 2:00 P.M. EST) – Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine. The findings will be presented Dec. 6, 2025, at the American Society of Hematology (ASH) annual meeting in Orlando.
None of the 18 patients who completed up to six cycles of treatment with the antibody linvoseltamab had detectable disease on highly sensitive tests. This preliminary ...
ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer
2025-12-06
Article Summary:
Researchers found that DNA’s shape matters. When its loops break, cancer can start.
Based on a new concept of architectural tumor suppression, researchers used proteins that organize DNA to also help prevent lymphoma.
Artificial intelligence helped reveal the changes that could guide future treatments.
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 6, 2025, AT 9:50 A.M. EST) – Cancer isn’t just about broken genes—it’s about broken architecture. Imagine a city where roads suddenly vanish, ...